Replimune prices $150M underwritten offering of common stock and pre-funded warrants
Replimune Group, Inc. (REPL) priced an underwritten offering of 9,701,490 shares and pre-funded warrants for 2,736,340 shares at $12.06 per share, expecting about $150.0 million in gross proceeds. Net proceeds are estimated at about $140.5 million. Securities delivery is expected around Aug. 11, 2026, subject to closing conditions.
How this was made
The 30-second read
Why it matters
Traders should focus on dilution math versus cash runway needs, and on how warrant terms may influence hedging and near-term supply/demand dynamics into the Aug 11 expected delivery.
Market read
A priced, underwritten equity raise with defined terms is a concrete, time-sensitive catalyst for the issuer’s stock and options positioning.
What to watch
Pre-funded warrants and the ownership cap mechanics (avoid >9.99% without notice) can affect who participates and how quickly dilution overhang becomes a trading factor.
Background
The company filed under a Form S-3 shelf registration and now priced a specific underwritten offering with pre-funded warrants.
Ticker impact
Replimune priced an underwritten common stock and pre-funded warrant offering to raise about $150M gross proceeds at $12.06 per share.
Likely near-term downside or volatility around the offering close, with sentiment dependent on use of proceeds and demand for the deal.
The article discloses the exact offering size, pricing, and warrant terms, which directly affect dilution expectations and financing risk.
Market effects
Biopharma equity issuance can signal financing needs and may modestly affect sentiment toward similarly sized clinical-stage names.
No specific regional spillover is indicated beyond US-listed small/mid-cap biotech financing.
Limited global relevance; this is company-specific capital raising.
Counterpoint
If proceeds materially extend runway or de-risk upcoming clinical milestones, the market may re-rate the stock after initial dilution concerns fade.
Key entities
- issuerReplimune Group, Inc.
Priced an underwritten offering of common stock and pre-funded warrants to raise about $150M gross proceeds.
- transaction_partyUnderwriters
Entered an underwriting agreement covering 9,701,490 shares and pre-funded warrants for 2,736,340 shares.
- filingSEC Form S-3 shelf registration (333-287536)
Shelf registration under which the prospectus supplement will be filed.
